- Home
- INCR vs IMUX Comparison
INCR vs IMUX Comparison
Compare INCR & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- IMUX
- Stock Information
- Founded
- INCR 1994
- IMUX 2016
- Country
- INCR Israel
- IMUX United States
- Employees
- INCR N/A
- IMUX N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- IMUX Health Care
- Exchange
- INCR Nasdaq
- IMUX Nasdaq
- Market Cap
- INCR 78.0M
- IMUX 92.2M
- IPO Year
- INCR N/A
- IMUX N/A
- Fundamental
- Price
- INCR $1.38
- IMUX $0.77
- Analyst Decision
- INCR
- IMUX Strong Buy
- Analyst Count
- INCR 0
- IMUX 5
- Target Price
- INCR N/A
- IMUX $6.00
- AVG Volume (30 Days)
- INCR 24.8K
- IMUX 1.3M
- Earning Date
- INCR 10-08-2025
- IMUX 11-13-2025
- Dividend Yield
- INCR N/A
- IMUX N/A
- EPS Growth
- INCR N/A
- IMUX N/A
- EPS
- INCR N/A
- IMUX N/A
- Revenue
- INCR $72,158,312.00
- IMUX N/A
- Revenue This Year
- INCR $69.54
- IMUX N/A
- Revenue Next Year
- INCR $41.75
- IMUX N/A
- P/E Ratio
- INCR N/A
- IMUX N/A
- Revenue Growth
- INCR N/A
- IMUX N/A
- 52 Week Low
- INCR $1.17
- IMUX $0.56
- 52 Week High
- INCR $1.79
- IMUX $1.42
- Technical
- Relative Strength Index (RSI)
- INCR 40.61
- IMUX 49.56
- Support Level
- INCR $1.31
- IMUX $0.67
- Resistance Level
- INCR $1.43
- IMUX $0.79
- Average True Range (ATR)
- INCR 0.06
- IMUX 0.05
- MACD
- INCR -0.00
- IMUX 0.00
- Stochastic Oscillator
- INCR 37.50
- IMUX 56.56
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.